Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HTR7 | P34969 | 4/20 | 0.34 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.30 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4291309 | 0.81 | LMNA (0.36) | LMNAMAPTHTR7 | |
| SCHEMBL4283648 | 0.80 | LMNA (0.43) | LMNA | |
| Hydrochloric Acid SCHEMBL4290934 | 0.79 | PARP1 (0.35) | LMNAMAPTHTR7 | |
| SCHEMBL4291290 | 0.72 | ALDH1A1 (0.51) | LMNA | |
| SCHEMBL4293871 | 0.72 | HPGD (0.51) | LMNAMAPTHTR7 | |
| SCHEMBL3648904 | 0.72 | LMNA (0.48) | LMNAMAPTHTR7 | |
| SCHEMBL14487357 | 0.70 | APEX1 (0.56) | LMNAMAPT | |
| SCHEMBL4750197 | 0.69 | LMNA (0.41) | LMNAMAPTHTR7 | |
| SCHEMBL4290177 | 0.69 | LMNA (0.45) | LMNA | |
| SCHEMBL1492377 | 0.68 | LMNA (0.44) | LMNAMAPTHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227560-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20090156612-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156612-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | LMNA 1785/4885MAPT 3142/4885HTR7 1874/4885 |
| US-20090227560-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | LMNA 1785/4885MAPT 3142/4885HTR7 1874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.